Gibson Dunn Advised Dianthus Therapeutics on $288 Million Offering of Common Stock and Pre-Funded Warrants
Firm News | September 12, 2025
Gibson Dunn advised Dianthus Therapeutics, Inc., a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, on its $288 million offering of common stock and pre-funded warrants.
Our corporate team was led by partners Ryan Murr, Branden Berns, and Melanie Neary and included associates Nicholas Linke, Jasmine Vitug, and Lauren Guzman.